INS and type 2 diabetes mellitus: However, given that DPPIV inhibitors have comparatively modest chronic glycemic efficacy in T2DM, averaging 0.3–0.5% HbA1c reduction, when detecting and validating a novel insulin secretory regulatory pathway of broad clinical relevance and interest we found it hard to argue for a lower efficacy threshold.